You are here

Article Text

Article menu

other Versions

Download PDFPDF
Editorial
Medicines optimisation opportunities: driving change?
  1. Michael Wilcock
  1. Pharmacy, Royal Cornwall Hospitals NHS Trust, Truro, UK
  1. Correspondence to Michael Wilcock; mike.wilcock{at}nhs.net

https://doi.org/10.1136/dtb.2024.000023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    NHS England published guidance on 16 national medicines optimisation ‘opportunities’ for integrated care boards (ICBs) in 2023.1 These were selected to support ICBs in tackling inequalities, improving outcomes and value for money, and relate to appropriate use, access and uptake of medicines.2 ICBs are recommended to choose at least five of these opportunities alongside their local medicines optimisation priorities. Data to measure ICB’s performance against these opportunities are available from several sources, including the NHS Business Services Authority (NHSBSA) and OpenPrescribing websites.3 4 The NHSBSA dashboard reports include problematic polypharmacy, valproate safety, low priority prescribing, prescribing of blood glucose ketone meters and testing strips, carbon emissions from inhalers, antibiotic course length, opioid use, best value direct-acting oral anticoagulants (DOACs) and best value biologics. …

    View Full Text

    Footnotes

    • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

    • Provenance and peer review Commissioned; externally peer reviewed.